Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) completed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in gross proceeds, according to a company statement.

The FDA granted the voucher in March 2026 following approval of KRESLADI, Rocket's gene therapy for severe leukocyte adhesion deficiency-I, a rare primary immunodeficiency condition.

The biotechnology company reported cash, cash equivalents and investments of $144.4 million as of March 31, 2026. The voucher sale proceeds increased the company's pro forma cash position to approximately $322.6 million, which Rocket expects will fund operations through the second quarter of 2028.

The priority review voucher allows pharmaceutical companies to receive expedited FDA review of a drug application, reducing the standard review timeline from 10 months to six months for a future product submission.

Rocket Pharmaceuticals develops gene therapies for rare cardiovascular diseases, with additional programs in hematology and immunology. The company's cardiovascular pipeline includes three clinical-stage programs targeting inherited cardiomyopathy subtypes: hypertrophic, arrhythmogenic, and dilated cardiomyopathies.